Twist Bioscience Co. (NASDAQ:TWST) Receives $51.90 Consensus Price Target from Analysts

Shares of Twist Bioscience Co. (NASDAQ:TWST) have earned a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $53.80.

Several equities research analysts have recently issued reports on TWST shares. Wolfe Research began coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. Scotiabank lifted their price target on Twist Bioscience from $54.00 to $62.00 and gave the stock a “sector outperform” rating in a report on Tuesday. Barclays dropped their price objective on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a report on Tuesday, November 19th. TD Cowen restated a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th. Finally, Leerink Partners upped their price target on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th.

Twist Bioscience Price Performance

TWST stock opened at $52.02 on Friday. The business’s 50-day moving average is $48.63 and its two-hundred day moving average is $46.21. The firm has a market capitalization of $3.09 billion, a P/E ratio of -14.45 and a beta of 1.87. Twist Bioscience has a 1 year low of $27.41 and a 1 year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 66.69% and a negative return on equity of 32.27%. The firm had revenue of $88.70 million for the quarter, compared to analysts’ expectations of $86.96 million. During the same quarter last year, the company earned ($0.75) earnings per share. The firm’s revenue was up 24.1% compared to the same quarter last year. On average, analysts expect that Twist Bioscience will post -2.27 EPS for the current year.

Insider Activity

In other news, COO Patrick John Finn sold 10,340 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $48.00, for a total value of $496,320.00. Following the completion of the sale, the chief operating officer now directly owns 221,061 shares of the company’s stock, valued at approximately $10,610,928. This represents a 4.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Paula Green sold 860 shares of the firm’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $52.70, for a total value of $45,322.00. Following the transaction, the senior vice president now directly owns 133,715 shares in the company, valued at approximately $7,046,780.50. This represents a 0.64 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 48,707 shares of company stock valued at $2,343,623. 3.01% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Van ECK Associates Corp grew its position in Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after buying an additional 267 shares during the last quarter. Signaturefd LLC boosted its holdings in shares of Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after acquiring an additional 306 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Twist Bioscience by 2.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company’s stock worth $734,000 after acquiring an additional 363 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after acquiring an additional 381 shares during the period. Finally, D.A. Davidson & CO. raised its holdings in Twist Bioscience by 3.5% during the third quarter. D.A. Davidson & CO. now owns 19,618 shares of the company’s stock worth $886,000 after purchasing an additional 664 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.